Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02612779 · OUTCOME

Objective Response Rate (ORR)

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. · Source last updated 2021-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent of Participants
Interval / dispersion
95% Confidence Interval
Time frame
From first dose to study completion date (up to approximately 50 months)

What was measured

ORR is defined as the percent of participants with best overall response of partial response (PR) or better. Response is determined per IMWG uniform criteria.

Analysis population: All treated participants

Groups in this outcome

EPd Cohort

Participants received treatment with Elotuzumab in combination with Pomalidomide and low-dose Dexamethasone in a 28 day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EPd Cohort68

Reported measurements

Source class 1
Values in Percent of Participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
EPd Cohort51.5Not reported39.0363.78Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        39.03
        upper Limit
        63.78
        value
        51.5
denoms
  1. counts
    1. group Id
      OG000
      value
      68
    units
    Participants
description
ORR is defined as the percent of participants with best overall response of partial response (PR) or better. Response is determined per IMWG uniform criteria.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received treatment with Elotuzumab in combination with Pomalidomide and low-dose Dexamethasone in a 28 day cycle.
    id
    OG000
    title
    EPd Cohort
param Type
NUMBER
population Description
All treated participants
reporting Status
POSTED
time Frame
From first dose to study completion date (up to approximately 50 months)
title
Objective Response Rate (ORR)
type
SECONDARY
unit Of Measure
Percent of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice